¼¼°èÀÇ ½Å°æÇÐ¿ë µðÁöÅÐ Çコ ½ÃÀå
Digital Health in Neurology
»óǰÄÚµå : 1786434
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 274 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½Å°æÇÐ¿ë µðÁöÅÐ Çコ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1,176¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 384¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½Å°æÇÐ¿ë µðÁöÅÐ Çコ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 20.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,176¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¼ÒÇÁÆ®¿þ¾î ±¸¼º¿ä¼Ò´Â CAGR 22.8%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 716¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Çϵå¿þ¾î ±¸¼º¿ä¼Ò ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 17.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 105¾ï ´Þ·¯, Áß±¹Àº CAGR 27.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Å°æÇÐ¿ë µðÁöÅÐ Çコ ½ÃÀåÀº 2024³â¿¡ 105¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 282¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 27.9%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 16.1%¿Í 18.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 17.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ½Å°æÇÐ¿ë µðÁöÅÐ Çコ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

AI¿Í µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿°¡ ½Å°æ Áø´ÜÀ» º¯È­½Ãų ¼ö ÀÖÀ»±î?

ÀΰøÁö´É(AI)°ú µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÅëÇÕÀº ½Å°æÇÐÀû Áø´Ü¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, °£Áú, ´Ù¹ß¼º °æÈ­Áõ µîÀÇ Áúº´À» Á¶±â¿¡ ¹ß°ßÇϰí Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ±âÁ¸ÀÇ ½Å°æÇÐÀû Áø´ÜÀº ÁÖ°üÀûÀÎ Æò°¡³ª Ŭ¸®´Ð¿¡¼­ÀÇ Æò°¡¿¡ ÀÇÁ¸ÇÏ´Â °æ¿ì°¡ ¸¹¾Æ Áø´ÜÀÌ ´Ê¾îÁö°Å³ª Àϰü¼º ¾ø´Â ¸ð´ÏÅ͸µÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ³ú ¿µ»ó µ¥ÀÌÅÍ¿Í ¾ð¾î ÆÐÅÏÀ» ºÐ¼®ÇÏ´Â ¸Ó½Å·¯´× ¸ðµ¨ µî AI ±â¹Ý µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀº ÀÓ»ó Æò°¡¿¡¼­ µå·¯³ªÁö ¾ÊÀ» ¼ö ÀÖ´Â ¹Ì¹¦ÇÑ ½Å°æÇÐÀû º¯È­¸¦ °¨ÁöÇÏ¿© Áø´ÜÀÇ Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­ ¹× ¸ð¹ÙÀÏ ±â¹Ý ÀÎÁö±â´É Æò°¡´Â ½Å°æÇÐÀû »óŸ¦ ¿ø°ÝÀ¸·Î ¸ð´ÏÅ͸µÇϰí Áúº´ ÁøÇà¿¡ ´ëÇÑ ½Ç½Ã°£ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ, AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ºÐ¼®À» ÅëÇØ ½Å°æÅðÇ༺ Áúȯ ¹ßº´ À§ÇèÀÌ ³ôÀº °³ÀÎÀ» ÆÄ¾ÇÇÏ¿© Á¶±â °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª µ¥ÀÌÅÍ Ç¥ÁØÈ­, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, AI ¸ðµ¨ °ËÁõ µîÀÇ °úÁ¦´Â ¿©ÀüÈ÷ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ÀÔ´Ï´Ù. µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¿Í AI ±â¹Ý ½Å°æÇÐ µµ±¸°¡ Áö¼ÓÀûÀ¸·Î °³¼±µÊ¿¡ µû¶ó, Á¤¹ÐÀÇ·á¿¡¼­ Çõ½ÅÀûÀÎ ¿ªÇÒÀ» ¼öÇàÇÏ¿© º¸´Ù Àû±ØÀûÀÌ°í °³ÀÎÈ­µÈ ½Å°æÇÐÀû Ä¡·á¸¦ Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¿ø°Ý ½Å°æÇÐÀº Àü¹® ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ¾î¶»°Ô È®ÀåÇϰí Àִ°¡?

¿ø°Ý ½Å°æÇÐÀÇ ±Þ¼ÓÇÑ º¸±ÞÀº ƯÈ÷ ½Å°æ°ú ÀÇ»çÀÇ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ ¼Ò¿Ü Áö¿ª°ú ¿Üµý Áö¿ª¿¡¼­ Àü¹®ÀûÀÎ ½Å°æÇÐ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¿ø°Ý ½Å°æÇÐ Ç÷§ÆûÀ» ÅëÇØ ³úÁ¹Áß, °£Áú, ÆíµÎÅë µîÀÇ ÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀº °¡»ó ¿¹¾àÀ» ÅëÇØ Àü¹®ÀÇÀÇ Áø·á¸¦ ¹ÞÀ» ¼ö ÀÖ¾î º´¿ø ¹æ¹®ÀÇ Çʿ伺À» ÁÙÀ̰í Ä¡·á °áÁ¤À» ½Å¼ÓÇÏ°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ÀÇ»ç°áÁ¤ Áö¿ø ½Ã½ºÅÛÀº ½Ç½Ã°£ ȯÀÚ µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ ÀÓ»óÀǰ¡ ½Å°æÁúȯÀ» Áø´ÜÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÔÀ¸·Î½á ¿ø°Ý ½Å°æÇÐ ¼­ºñ½º¸¦ ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ³úÆÄ(EEG) ¸ð´ÏÅ͸µ°ú ¸ð¹ÙÀÏ ±â¹Ý ½Å°æÇÐÀû Æò°¡µµ ¿ø°ÝÀÇ·á Ç÷§Æû¿¡ ÅëÇյǾî Áö¼ÓÀûÀΠȯÀÚ Æò°¡¿Í Àû½Ã °³ÀÔÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¿ø°Ý ½Å°æÇÐ µµÀÔÀº »óȯ Á¤Ã¥, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹®Á¦, Áö¹æÀÇ °íµµÀÇ ÀÎÇÁ¶ó Çʿ伺 µîÀÇ À庮¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí, ¿ø°Ý ½Å°æÇÐÀÇ È®´ë´Â Àü¹®°¡¿¡ ÀÇÇÑ ½Å°æÇÐÀû Ä¡·á¸¦ º¸´Ù Á¢±ÙÇϱ⠽±°í, ºñ¿ë È¿À²ÀûÀ̸ç, È¿À²ÀûÀ¸·Î Á¦°øÇÔÀ¸·Î½á ȯÀÚµéÀÇ ¿¹Èĸ¦ Å©°Ô °³¼±ÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

µðÁöÅÐ Ä¡·áÁ¦(DTx)°¡ ½Å°æÁúȯ °ü¸®¸¦ °³¼±ÇÒ ¼ö ÀÖÀ»±î?

µðÁöÅÐ Ä¡·á(DTx)´Â ¾à¸®ÇÐÀû Ä¡·á¸¦ º¸¿ÏÇÏ´Â Áõ°Å ±â¹ÝÀÇ ¼ÒÇÁÆ®¿þ¾î ±â¹Ý ÁßÀ縦 Á¦°øÇÔÀ¸·Î½á ½Å°æ ÁúȯÀ» °ü¸®Çϴ ȹ±âÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÆíµÎÅë, ´Ù¹ß¼º °æÈ­Áõ, °£Áú°ú °°Àº ½Å°æÁúȯÀº Àå±âÀûÀÎ Áúȯ °ü¸®°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹Áö¸¸, º¹¾à ¼øÀÀµµ ¹®Á¦³ª Áõ»óÀÇ º¯È­·Î ÀÎÇØ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖ½À´Ï´Ù. AI ±â¹Ý DTx Ç÷§ÆûÀº °³ÀÎÈ­µÈ ÀÎÁö ÈÆ·Ã, Çൿ Ä¡·á ¸ðµâ, ½Ç½Ã°£ Áõ»ó ÃßÀûÀ» Á¦°øÇÏ¿© ȯÀÚÀÇ ¼øÀÀµµ ¹× Àü¹ÝÀûÀÎ Áúº´ °ü¸®¸¦ °³¼±ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, µðÁöÅÐ ÀÎÁö ÈÆ·Ã ¾ÖÇø®ÄÉÀ̼ÇÀº ¾ËÃ÷ÇÏÀ̸Ӻ´ ȯÀÚÀÇ ÀÎÁö ±â´É ÀúÇϸ¦ ´ÊÃß±â À§ÇØ »ç¿ëµÇ°í ÀÖÀ¸¸ç, µðÁöÅÐ ÀçȰ ÇÁ·Î±×·¥Àº ³úÁ¹Áß È¯ÀÚÀÇ ¿îµ¿ ±â´É ȸº¹À» µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, VRÀ» ÀÌ¿ëÇÑ Ä¡·á´Â ½Å°æÁúȯ¿¡ µû¸¥ ¸¸¼º ÅëÁõ°ú ºÒ¾È°¨ °ü¸®¿¡µµ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú º¸Çè Àû¿ëÀÌ º¸±ÞÀÇ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. DTxÀÇ È¿°ú¸¦ µÞ¹ÞħÇÏ´Â ÀÓ»óÀû ±Ù°Å°¡ °è¼Ó Áõ°¡Çϰí ÀÖ´Â °¡¿îµ¥, µðÁöÅÐ Ä¡·áÁ¦´Â ½Å°æ°ú ÀÇ·á¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸®Àâ¾Æ ȯÀÚ Âü¿©¿Í Àå±âÀûÀÎ °Ç°­ °á°ú¸¦ °³¼±ÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

½Å°æÇÐ¿ë µðÁöÅÐ Çコ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

½Å°æÇÐ¿ë µðÁöÅÐ Çコ ½ÃÀåÀÇ ¼ºÀåÀº ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡, AI ±â¹Ý Áø´ÜÀÇ Ã¤Åà Áõ°¡, ¿þ¾î·¯ºí ½Å°æÇÐ ¸ð´ÏÅ͸µ ±â±âÀÇ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¹× ¿ø°Ý ½Å°æÇÐ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ƯÈ÷ ½Å°æ°ú Àǻ翡 ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ Áö¿ª¿¡¼­ ½ÃÀå È®´ë¸¦ ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¿Í ¿¹Ãø ºÐ¼®ÀÇ ÅëÇÕÀº Áúº´ÀÇ Á¶±â ¹ß°ßÀ» °³¼±ÇÏ°í ½Å°æ ÅðÇ༺ ÁúȯÀ» º¸´Ù Àû±ØÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ°Ô ÇÕ´Ï´Ù. ½Å°æ Áúȯ¿¡ ´ëÇÑ µðÁöÅÐ Ä¡·á(DTx)ÀÇ È®´ë´Â ±âÁ¸ Ä¡·á¸¦ º¸¿ÏÇÏ´Â ºñħ½ÀÀû ¼ÒÇÁÆ®¿þ¾î ±â¹Ý ÁßÀ縦 Á¦°øÇÏ¿© º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ Çコ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú ½Å°æÇп¡ ƯȭµÈ µðÁöÅÐ Çコ ½ºÅ¸Æ®¾÷¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. AI, ºòµ¥ÀÌÅÍ, ¸ð¹ÙÀÏ Çコ ±â¼úÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀº ½Å°æÇÐÀÇ Àü¸ÁÀ» À籸¼ºÇϰí Áø´Ü°ú Ä¡·á¸¦ º¸´Ù Á¢±ÙÇϱ⠽±°í, È¿À²ÀûÀ̸ç, °³ÀÎÈ­ÇÒ ¼ö ÀÖµµ·Ï ÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

ºÎ¹®

±¸¼º¿ä¼Ò(¼ÒÇÁÆ®¿þ¾î ±¸¼º¿ä¼Ò, Çϵå¿þ¾î ±¸¼º¿ä¼Ò, ¼­ºñ½º), ÃÖÁ¾»ç¿ëÀÚ(ȯÀÚ ÃÖÁ¾»ç¿ëÀÚ, ÇÁ·Î¹ÙÀÌ´õ ÃÖÁ¾»ç¿ëÀÚ, ÁöºÒÀÚ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Digital Health in Neurology Market to Reach US$117.6 Billion by 2030

The global market for Digital Health in Neurology estimated at US$38.4 Billion in the year 2024, is expected to reach US$117.6 Billion by 2030, growing at a CAGR of 20.5% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$71.6 Billion by the end of the analysis period. Growth in the Hardware Component segment is estimated at 17.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.5 Billion While China is Forecast to Grow at 27.9% CAGR

The Digital Health in Neurology market in the U.S. is estimated at US$10.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$28.2 Billion by the year 2030 trailing a CAGR of 27.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.1% and 18.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.2% CAGR.

Global Digital Health in Neurology Market - Key Trends & Drivers Summarized

Can AI and Digital Biomarkers Transform Neurological Diagnosis?

The integration of artificial intelligence (AI) and digital biomarkers is revolutionizing neurological diagnosis, enabling early detection and continuous monitoring of conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis. Traditional neurological diagnostics often rely on subjective assessments and in-clinic evaluations, which can lead to delayed diagnoses and inconsistent monitoring. AI-driven digital health solutions, including machine learning models analyzing brain imaging data and speech patterns, are enhancing diagnostic accuracy by detecting subtle neurological changes that may not be evident in clinical evaluations. Wearable biosensors and mobile-based cognitive assessments are further enabling remote monitoring of neurological conditions, providing real-time insights into disease progression. Additionally, AI-powered predictive analytics are being used to identify individuals at high risk of developing neurodegenerative disorders, allowing for early interventions. However, challenges such as data standardization, regulatory approvals, and AI model validation still need to be addressed. As digital biomarkers and AI-driven neurology tools continue to improve, they are expected to play a transformative role in precision medicine, offering more proactive and personalized neurological care.

How Is Tele-Neurology Expanding Access to Specialized Care?

The rapid adoption of tele-neurology is improving access to specialized neurological care, particularly in underserved and remote regions where neurologist availability is limited. Tele-neurology platforms allow patients with conditions such as stroke, epilepsy, and migraine disorders to receive expert consultations via virtual appointments, reducing the need for hospital visits and expediting treatment decisions. AI-powered decision support systems are further enhancing tele-neurology services by assisting clinicians in diagnosing neurological disorders through real-time patient data analysis. Remote EEG (electroencephalography) monitoring and mobile-based neurological assessments are also being integrated into telehealth platforms, ensuring continuous patient evaluation and timely interventions. However, tele-neurology adoption faces barriers such as reimbursement policies, data privacy concerns, and the need for advanced infrastructure in rural areas. Despite these challenges, the expansion of tele-neurology is expected to drive significant improvements in patient outcomes by making expert neurological care more accessible, cost-effective, and efficient.

Can Digital Therapeutics (DTx) Improve Neurological Disease Management?

Digital therapeutics (DTx) are emerging as a groundbreaking solution for managing neurological disorders by offering evidence-based, software-driven interventions that complement pharmacological treatments. Neurological conditions such as migraine, multiple sclerosis, and epilepsy often require long-term disease management, which can be challenging due to medication adherence issues and fluctuating symptoms. AI-driven DTx platforms provide personalized cognitive training, behavioral therapy modules, and real-time symptom tracking to improve patient adherence and overall disease management. For instance, digital cognitive training applications are being used to slow cognitive decline in Alzheimer’s patients, while digital rehabilitation programs are helping stroke survivors regain motor function. Additionally, VR-based therapies are proving effective in managing chronic pain and anxiety associated with neurological conditions. However, regulatory approvals and insurance coverage remain barriers to widespread adoption. As clinical evidence supporting DTx effectiveness continues to grow, digital therapeutics are expected to become an integral part of neurology care, improving patient engagement and long-term health outcomes.

What Is Driving the Growth of the Digital Health in Neurology Market?

The growth in the digital health in neurology market is driven by several factors, including increasing prevalence of neurological disorders, rising adoption of AI-driven diagnostics, and advancements in wearable neurology monitoring devices. The growing demand for remote patient monitoring and tele-neurology services is further accelerating market expansion, especially in regions with limited access to neurologists. The integration of digital biomarkers and predictive analytics is improving early disease detection, enabling more proactive management of neurodegenerative disorders. The expansion of digital therapeutics (DTx) for neurological conditions is also driving adoption, offering non-invasive, software-based interventions that complement traditional treatments. Additionally, regulatory support for digital health solutions and increasing investments in neurology-focused digital health startups are fueling market growth. As AI, big data, and mobile health technologies continue to evolve, digital health solutions are expected to reshape the neurology landscape, making diagnosis and treatment more accessible, efficient, and personalized.

SCOPE OF STUDY:

The report analyzes the Digital Health in Neurology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Software Component, Hardware Component, Services); End-Use (Patients End-Use, Providers End-Use, Payers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â